Market Research Report
Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Disease and Application
|Human Microbiome Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Disease and Application|
Published: August 24, 2021
The Insight Partners
Content info: 188 Pages
Delivery time: 1-2 business days
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028.
The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing. However, strict government guidelines and lack of knowledge about detailed examination hinder the market growth.
Humans coexist with the diverse microbial species inhabiting within and on the surface of their bodies. Recent studies have highlighted that these microbial communities are essentially serving as another organ of the body as they play crucial roles in human physiology and disease progression. Several basic and translational research efforts have been initiated to focus on deciphering the microbiome function and its benefits to the human health. Many human medical conditions, such as inflammatory bowel diseases and obesity, have been closely associated with the composition of the gut microbial community; furthermore, conditions such as asthma and diabetes are thought to be influenced this microbial community. Many efforts are being taken to alter the gut microbiome to eradicate several diseases. Probiotics, prebiotics dietary supplements, and foods that contain live microbes have been studied thoroughly to assess their effects on human health. Also, several companies are designing and developing various microbiome therapies. Rebiotix Inc. has developed Microbiota Restoration Therapy (MRT) drug platform for delivering healthy, live, human-derived microbes into a sick patient's intestinal tract to treat disease. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.
Based on product, the human microbiome market is further segmented into foods, medical foods, probiotics, prebiotics, drugs, diagnostic devices, and supplements. The market, by disease, is segmented into diabetes, cancer, autoimmune disorders, obesity, mental disorders, and other diseases. In 2021, the obesity segment is likely to hold the largest share of the market, whereas the market for the diabetes segment is expected to grow at the fastest CAGR during the forecast period. The surging prevalence of diabetes and growing research for treatment of diabetes are driving the growth of the human microbiome market.
The World Health Organization (WHO), National Health Service (NHS), Centers for Disease Control and Prevention (CDC), Centers for Medicare and Medicaid Services, American Academy of Dermatology, and company websites are among the major primary and secondary sources referred to while preparing the report on the human microbiome market.
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.